ADC Net Income Per Share from 2010 to 2025

ADCT Stock  USD 1.83  0.08  4.57%   
ADC Therapeutics Net Loss yearly trend continues to be comparatively stable with very little volatility. Net Loss will likely drop to -3.55 in 2025. From the period from 2010 to 2025, ADC Therapeutics Net Loss quarterly data regression had r-value of (0.80) and coefficient of variation of (38.80). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(3.38)
Current Value
(3.55)
Quarterly Volatility
0.84548939
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ADC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADC Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 5 M, Depreciation And Amortization of 2.7 M or Interest Expense of 55.9 M, as well as many indicators such as Price To Sales Ratio of 2.13, Dividend Yield of 0.0 or Days Sales Outstanding of 228. ADC financial statements analysis is a perfect complement when working with ADC Therapeutics Valuation or Volatility modules.
  
Check out the analysis of ADC Therapeutics Correlation against competitors.

Latest ADC Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of ADC Therapeutics SA over the last few years. It is ADC Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ADC Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

ADC Net Income Per Share Regression Statistics

Arithmetic Mean(2.18)
Geometric Mean2.04
Coefficient Of Variation(38.80)
Mean Deviation0.73
Median(1.53)
Standard Deviation0.85
Sample Variance0.71
Range2.2384
R-Value(0.80)
Mean Square Error0.27
R-Squared0.65
Significance0.0002
Slope(0.14)
Total Sum of Squares10.72

ADC Net Income Per Share History

2025 -3.55
2024 -3.38
2023 -2.94
2022 -1.99
2021 -3.0
2020 -3.77
2019 -1.74

About ADC Therapeutics Financial Statements

ADC Therapeutics shareholders use historical fundamental indicators, such as Net Income Per Share, to determine how well the company is positioned to perform in the future. Although ADC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ADC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ADC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(3.38)(3.55)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.